Marine Bioactive Compound Discovery by Combining Virtual with Actual Laboratory Experiments

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Chemoecology for Drug Discovery".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 1869

Special Issue Editor

South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou, China
Interests: marine natural product; drug leads; pharmacological mechanism; marine microorganisms; cyanobacteria
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,                

Discovering new marine bioactive compounds is a challenging and time-consuming process that involves multiple intricate steps. One approach to expedite the discovery of these compounds is integrating virtual experiments with actual laboratory experiments. In recent years, there has been an increasing interest in combining computational and experimental methods to accelerate the identification of novel marine bioactive compounds. This innovative strategy, known as "computational experimentation", harnesses the capabilities of advanced computational techniques, including molecular docking, molecular dynamics simulations, and machine learning algorithms, to efficiently and cost-effectively identify and prioritize potential bioactive compounds. Virtual experiments employ mathematical models and algorithms within computer simulations to predict compound properties and activities based on their chemical structures. Actual laboratory experiments involve performing physical tests to measure the effects of these compounds on biological targets, such as cells, enzymes, or organisms.

The integration of virtual and actual laboratory experiments presents a promising approach for the discovery of marine bioactive compounds, thereby enhancing the efficiency and effectiveness of the discovery process. This convergence can ultimately lead to the development of novel products with potential benefits for human health and well-being.

This Special Issue will focus on employing advances in all aspects of marine natural products (MNPs) for drug discovery and development by combining virtual and actual laboratory experiments, including the following aspects:

  • Structurally novel and bioactive MNPs;
  • Predictive models of structure and function of MNPs;
  • Efficacy and pharmacological mechanisms of MNPs;
  • Total synthesis, optimization, or biosynthesis of bioactive or novel MNPs;
  • Research into marine medicinal biological resources.

Dr. Bin Yang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine natural products
  • biological activity
  • biosynthetic pathway
  • structure–activity relationships
  • molecular docking
  • network pharmacology
  • experimental validation
  • molecular networking
  • molecular dynamics simulations
  • machine learning algorithms

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 3079 KiB  
Article
Inhibition Effects and Mechanisms of Marine Compound Mycophenolic Acid Methyl Ester against Influenza A Virus
by Zihan Wang, Lishan Sun, Hongwei Zhao, Mamadou Dioulde Sow, Yang Zhang and Wei Wang
Mar. Drugs 2024, 22(5), 190; https://doi.org/10.3390/md22050190 - 23 Apr 2024
Viewed by 476
Abstract
Influenza A virus (IAV) can cause infection and illness in a wide range of animals, including humans, poultry, and swine, and cause annual epidemics, resulting in thousands of deaths and millions of hospitalizations all over the world. Thus, there is an urgent need [...] Read more.
Influenza A virus (IAV) can cause infection and illness in a wide range of animals, including humans, poultry, and swine, and cause annual epidemics, resulting in thousands of deaths and millions of hospitalizations all over the world. Thus, there is an urgent need to develop novel anti-IAV drugs with high efficiency and low toxicity. In this study, the anti-IAV activity of a marine-derived compound mycophenolic acid methyl ester (MAE) was intensively investigated both in vitro and in vivo. The results showed that MAE inhibited the replication of different influenza A virus strains in vitro with low cytotoxicity. MAE can mainly block some steps of IAV infection post adsorption. MAE may also inhibit viral replication through activating the cellular Akt-mTOR-S6K pathway. Importantly, oral treatment of MAE can significantly ameliorate pneumonia symptoms and reduce pulmonary viral titers, as well as improving the survival rate of mice, and this was superior to the effect of oseltamivir. In summary, the marine compound MAE possesses anti-IAV effects both in vitro and in vivo, which merits further studies for its development into a novel anti-IAV drug in the future. Full article
Show Figures

Figure 1

11 pages, 2143 KiB  
Article
Pestalotiopols E–J, Six New Polyketide Derivatives from a Marine Derived Fungus Pestalotiopsis sp. SWMU-WZ04-1
by Liyuan Jiang, Baorui Teng, Mengyu Zhang, Siwei Chen, Dan Zhang, Longfei Zhai, Jiafu Lin and Hui Lei
Mar. Drugs 2024, 22(1), 15; https://doi.org/10.3390/md22010015 - 26 Dec 2023
Viewed by 1209
Abstract
Chemical epigenetic cultivation of the sponge-derived fungus Pestalotiopsis sp. SWMU-WZ04-1 contributed to the identification of twelve polyketide derivatives, including six new pestalotiopols E–J (16) and six known analogues (712). Their gross structures were deduced from [...] Read more.
Chemical epigenetic cultivation of the sponge-derived fungus Pestalotiopsis sp. SWMU-WZ04-1 contributed to the identification of twelve polyketide derivatives, including six new pestalotiopols E–J (16) and six known analogues (712). Their gross structures were deduced from 1D/2D NMR and HRESIMS spectroscopic data, and their absolute configurations were further established by circular dichroism (CD) Cotton effects and the modified Mosher’s method. In the bioassay, the cytotoxic and antibacterial activities of all compounds were evaluated. Chlorinated benzophenone derivatives 7 and 8 exhibited inhibitory effects on Staphylococcus aureus and Bacillus subtilis, with MIC values varying from 3.0 to 50 μg/mL. In addition, these two compounds were cytotoxic to four types of human cancer cells, with IC50 values of 16.2~83.6 μM. The result showed that compound 7 had the probability of being developed into a lead drug with antibacterial ability. Full article
Show Figures

Figure 1

Back to TopTop